We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
New research published in the NEJM Evidence shows potential for Nordic Bioscience’s PRO-C6 assay becoming a next-generation biomarker in trials studying patients with heart failure with preserved ejection fraction (HFpEF). Read More
An experimental radiotracer known as [18F]flurpiridaz has met its two primary endpoints of exceeding a 60 percent threshold for both sensitivity and specificity in detecting coronary artery disease (CAD), according to the sponsors, GE Healthcare and Lantheus. Read More
All people are not the same. While glaringly obvious, that truth is often ignored in clinical trials. And fixing that problem requires companies to understand and overcome a myriad of barriers, according to a panel discussion held at the annual meeting of the Regulatory Affairs Professionals Society (RAPS) in Phoenix this week. Read More
CAREstream Medical drew an FDA Form 483 citing various failures in documentation following an agency inspection of the company’s Maitland, Fla., facility from April 25-27. Read More